2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 848

Efficacy of Prucalopride in the Treatment of Systemic Sclerosis-Related Intestinal Involvement: Results from an Open Label Cross-over Study
Abstract Number: 1896

Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases
Abstract Number: 2894

Efficacy of Rituximab in Systemic Sclerosis with Interstitial Lung Disease
Abstract Number: 3224

Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Based upon Prior Use of Non-Anti-TNF Biologics in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global Phase 3 Study
Abstract Number: 1736

Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study
Abstract Number: 1609

Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials
Abstract Number: 1117

EGCG Down-Regulates TNF-α-Induced Mcl-1 Expression By Modulating Mule/Huwe1, β-TrCP, and USP9X Ubiquitin/De-Ubiquitin Ligases in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2672

Elderly Patients Risk a False Positive Diagnosis of Primary Sjogren’s Syndrome If a Positive Labial Gland Biopsy Is Solely Based on Focus Score
Abstract Number: 1483

Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk
Abstract Number: 2725

Elevated Disease Activity in Disease-Related Spondyloarthritis Despite Use of Tumor Necrosis Factor Inhibitor Therapies
Abstract Number: 1904

Elevated GITRL Is Associated with Multi-Organ Involvement and Increased Disease Activity of Primarty Sjogren’s Syndrome and Promotes Pathogenic Th1/17 Differentiation
Abstract Number: 2706

Elevated Levels of Serum Myeloid Related Protein 8/14 in Ankylosing Spondylitis: Associated with Peripheral Arthritis and Active Disease
Abstract Number: 2577

Elevated Matrix Metalloproteinases Levels in Oral Fluids of Most Rheumatoid Arthritis Patients, Even without Frank Periodontitis
Abstract Number: 3017

Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis
Abstract Number: 1839

Elevated Plasma Cell-Free Mitochondrial DNA Defines a Subgroup of Lupus Patients with Membranous Lupus Nephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].